A fourth coronavirus vaccine is heading to the United States

A fourth coronavirus vaccine is heading to the United States; Scientists say the shooting could end the epidemic.

 A fourth vaccine for the Coronavirus is making its way to the United States.

Health experts say the vaccine, Covavax, is the most effective to date in showing protection against the original COVID-19 strain but also against variants of concern.

Researchers from 113 sites across the country evaluated 29,000 infected patients. Study results showed that it was 100% effective against the original SARs-CoV-2 and 93% effective against alpha and delta strains, both of which are on the WHO's List of Variants of Concern.

But what sets Covavax apart from the companies Pfizer, Moderna, and Johnson & Johnson?

Stephen Wallace, who leads the Global External Relations Strategies and COVID-19 Prevention Network at the Fred Hutchinson Cancer Research Center, receives a second injection from Dr. Tia Babu during the Phase 3 clinical trial of the Novavax COVID-19 vaccine at the UW Virology Research Clinic on February 12, 2021. in Seattle

Dr. Christopher Dohring, vice president of medical affairs at Franciscan Health, told News 8. "What they're doing is producing an immune protein, which appears to be a consistent part of the coronavirus as the virus mutates." A piece that helps deliver the vaccine to the human body and allows the immune system to recognize it and develop a strong response effectively. "

Premium content

Not only does Covavax offer high protection, Doehring says, but the side effects are much milder compared to other vaccines. 

The European Union create a deal with the drug company responsible for developing the vaccine, Novavax. They will buy 200 million doses of the vaccine.

Novavax is expected to apply for an emergency use authorization in the US by the end of the year.